Spotlight Therapeutics In vivo gene editing Illuminating cures within the genome
Investors 4
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.03.2022 | Series B | $36.5M | - |
| 30.11.2020 | Series A | $30M | GV |
Mentions in press and media 4
| Date | Title | Description |
| 22.03.2022 | Spotlight Therapeutics Raises $36.5M in Series B Funding | Spotlight Therapeutics, Inc., a Hayward, California-based biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, raised $36.5M in Series B financing.
The round was co-led by new investors... |
| 22.03.2022 | Spotlight Therapeutics Raises $36.5M Series B |
SAN FRANCISCO, CA, Spotlight Therapeutics today announced a $36.5 million Series B financing to fuel a drive toward the clinic.
>> Click here for more funding data on Spotlight Therapeutics
>> To export Spotlight Therapeutic... |
| 02.12.2020 | Daily funding roundup - Dec. 1st, 2020 | WaveOne has raised $6.5M; Databand landed $14.5M; Proscia has secured $23M
Reposite: Reposite is a New York-based maker of a database that helps travel agents manage suppliers and clients, track proposals. Reposite and better manage their b... |
| 30.11.2020 | Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics | Spotlight Therapeutics, Inc., a biotechnology company developing non-viral gene editing therapeutics for direct in vivo editing of target genes, closed its Series A financing bringing the total raised to $30 million. The financing was led b... |
Reviews 0
